Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods: All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results: Eighty-eight patients were included. Most patients had received previous infliximab treatment. Clinical remission rates were 17%, 28.4%, 36.4% and 43.2% at 4, 12, 24 and 54 weeks respectively. Twenty-two patients required colectomy. Clinical remission and low C-reactive protein at week 12 predicted clinical remission at week 54 (OR 4.17, 95% CI 2.36-19.44; OR 2.63, 95% CI 2.32-14.94, respectively). Previous immunosuppressant use was associated with a lower probability of clinical remission at week 54 (OR 0.67, 95% CI 0.08-0.66) and with a higher rate of colectomy (HR 9.7, 95% CI 1.46-9.07). Conclusion: In this large "real-life" experience adalimumab appears effective in patients with otherwise medically refractory ulcerative colitis. Patients achieving early remission can expect a better long-term outcome.

Adalimumab in active ulcerative colitis: A "real-life" observational study / A. Armuzzi, L. Biancone, M. Daperno, A. Coli, D. Pugliese, V. Annese, A. Aratari, S. Ardizzone, P. Balestrieri, F. Bossa, M. Cappello, F. Castiglione, M. Cicala, S. Danese, R. D'Incà, P. Dulbecco, G. Feliciangeli, W. Fries, S. Genise, P. Gionchetti, S. Gozzi, A. Kohn, R. Lorenzetti, M. Milla, S. Onali, A. Orlando, L. Giovanni Papparella, S. Renna, C. Ricci, F. Rizzello, R. Sostegni, L. Guidi, C. Papi. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 45:9(2013 Sep), pp. 738-743. [10.1016/j.dld.2013.03.018]

Adalimumab in active ulcerative colitis: A "real-life" observational study

Ardizzone, Sandro;Ricci, Chiara;
2013-09

Abstract

Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods: All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results: Eighty-eight patients were included. Most patients had received previous infliximab treatment. Clinical remission rates were 17%, 28.4%, 36.4% and 43.2% at 4, 12, 24 and 54 weeks respectively. Twenty-two patients required colectomy. Clinical remission and low C-reactive protein at week 12 predicted clinical remission at week 54 (OR 4.17, 95% CI 2.36-19.44; OR 2.63, 95% CI 2.32-14.94, respectively). Previous immunosuppressant use was associated with a lower probability of clinical remission at week 54 (OR 0.67, 95% CI 0.08-0.66) and with a higher rate of colectomy (HR 9.7, 95% CI 1.46-9.07). Conclusion: In this large "real-life" experience adalimumab appears effective in patients with otherwise medically refractory ulcerative colitis. Patients achieving early remission can expect a better long-term outcome.
Adalimumab; "Real-life" study; Ulcerative colitis
Settore MED/12 - Gastroenterologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1590865813001369.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 651.37 kB
Formato Adobe PDF
651.37 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/641193
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 61
social impact